BIA member, RBW Consulting has just been named winner in the Best Corporate Social Responsibility category at the 2022 Best Business Awards. The award was in recognition of work tied to its IMPACT programme, which in the last year focused on a research initiative into the mental health impact of a rare disease diagnosis. The project has been recognised and endorsed by individuals and organisations from the rare disease community and was presented to over 150 people via webinar at launch.
“… For us to drive innovation that addresses the diverse healthcare needs of our global society, we need a diverse team…”
In the next interview in our Diversity, Equity & Inclusion Leadership series, we spoke to Tomoko Adachi, General Manager of Global HR and HR Business Partner for the Cardiac and Vascular Company at Terumo Corporation. Tomoko shares her insights in good D, E & I practice from her recent experience in medtech and compares this with what she has seen in the tech world, drawing on her 29-year tenure with Sony before Terumo.
eXmoor Pharma has outlined its ambitious global growth strategy for the next 18 months during a visit from the Minister for Science Research and Innovation, George Freeman MP.
Unveiling its plans to be the flagship tenant-business at Bristol’s Patchway Trading estate, eXmoor CEO Angela Osborne met with George Freeman on Friday 10 June and discussed the importance of Government support in creating a new South West regional cell and gene therapy manufacturing cluster.
The Cell and Gene Therapy Catapult (CGT Catapult) and the UK Dementia Research Institute (UK DRI) today announce a collaboration to accelerate the clinical development of adeno-associated virus (AAV) based gene therapies for dementia.
Discovery Park has signed a Memorandum of Understanding (MoU) with Oyster Venture Partners in a collaboration which will help drive investment and accelerate the creation of a Neuroscience Centre of Excellence at the Kent site.
The partnership will also support the growth of Discovery Park based companies and provide potential investment opportunities for Discovery Park Ventures.
Stablepharma Ltd., a UK-based biotechnology company pioneering fridge-free vaccines today announced a collaboration agreement with a world leader in sterile manufacturing and serving science, to manufacture thermostable Tetanus diphtheria (Td) vaccines at their facilities in Italy.